ABBV vs MCD: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and McDonald's Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-16.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
McDonald's Corporation · Consumer Cyclical
$252.78
+40.7% upside to fair value
Med Conviction
Grade A
High Quality
QuantHub Verdict
MCD has more upside to fair value
(+40.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MCD |
| Current Price |
$261.70 |
$252.78 |
| Fair Value Estimate |
$259.04 |
$355.71 |
| Upside to Fair Value |
-1.0%
|
+40.7%
|
| Market Cap |
$462.4B |
$179.6B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
15.5x
|
| Price / Sales |
7.2x
|
6.5x
|
| Price / FCF |
23.6x
|
23.1x
|
| Revenue Growth YoY |
+10.2%
|
+3.8%
|
| Gross Margin |
71.5%
|
57.4%
|
| Operating Margin |
29.3%
|
45.8%
|
| Return on Equity |
-136.5%
|
-561.2%
|
| Dividend Yield |
2.61% |
2.94% |
| FCF Yield |
4.25%
|
4.32%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
McDonald's operates a globally scaled, approximately 95% franchised restaurant system with 46,028 restaurants in more than 100 countries, combining a powerful consumer brand, real-estate-backed franchise economics, supplier scale and digital loyalty reach. Business quality is high despite meaningful leverage: TTM gross, operating and net margins are 57.4%, 45.8% and 31.7%, respectively, while loy…
Accumulation Zones
| Metric |
ABBV |
MCD |
| Zone Low |
$194.28 |
$266.78 |
| Zone High |
$220.18 |
$302.35 |
| In Buy Zone? |
No
|
Yes
|